{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-012510","form_type":"8-K","ticker":"NMTC","cik":"0001500198","company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","filed_at":"2025-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.804509+00:00","generated_at":"2026-05-26T22:49:52.131590+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"NeuroOne Q1 FY2025 revenue $6.3M, net income $1.8M; reaffirms FY guidance","bullets":["Product revenue $3.3M (+235% YoY); license revenue $3.0M from expanded Zimmer Biomet deal.","Net income $1.8M ($0.06 EPS) vs net loss of $3.3M ($0.14 loss) in prior year.","Product gross margin improved to 58.9% from 27.2%; FY2025 product revenue outlook $8-10M reaffirmed.","Regained Nasdaq compliance; debt-free with $1.1M cash and $4.1M working capital.","OneRF placed in 5 epilepsy centers; FDA 510(k) submission for trigeminal nerve ablation expected H1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-012510","json":"https://secwatch.observer/filing/0001213900-25-012510.json","markdown":"https://secwatch.observer/filing/0001213900-25-012510.md","text":"https://secwatch.observer/filing/0001213900-25-012510.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1500198/000121390025012510/0001213900-25-012510-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1500198/000121390025012510/ea0230716-8k_neuroone.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T22:49:52.131590+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}